[go: up one dir, main page]

CN101575319B - Process for preparing lapatinib synthetic intermediate - Google Patents

Process for preparing lapatinib synthetic intermediate Download PDF

Info

Publication number
CN101575319B
CN101575319B CN2009100333278A CN200910033327A CN101575319B CN 101575319 B CN101575319 B CN 101575319B CN 2009100333278 A CN2009100333278 A CN 2009100333278A CN 200910033327 A CN200910033327 A CN 200910033327A CN 101575319 B CN101575319 B CN 101575319B
Authority
CN
China
Prior art keywords
chloro
iodo
aminobenzonitrile
dma
dmf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009100333278A
Other languages
Chinese (zh)
Other versions
CN101575319A (en
Inventor
李飞
王武伟
季兴
许贯虹
殷晓佳
孙旭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Medical University
Original Assignee
Nanjing Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Medical University filed Critical Nanjing Medical University
Priority to CN2009100333278A priority Critical patent/CN101575319B/en
Publication of CN101575319A publication Critical patent/CN101575319A/en
Application granted granted Critical
Publication of CN101575319B publication Critical patent/CN101575319B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to a process for preparing a lapatinib synthetic intermediate, which is characterized by comprising the following process steps: mixing 5-iodo-2-aminobenzonitrile and DMF-DMA; heating and refluxing the mixture at a temperature of between 90 and 100 DEG C for 1 to 2 hours, and performing reduced pressure distillation at a pressure of 0.1 MPa and at a temperature of between 70 and 80 DEG C for 10 to 30 minutes to remove excessive DMF-DMA; adding glacial acetic acid and 3-chloro-4-(3-fluorophenyl-methoxy) aniline; heating and refluxing the mixture at a temperature of between90 and 100 DEG C for 1 hour, cooling the mixture to the room temperature, and pouring the mixture to ice water; performing vacuum filtration, and washing a filter cake with the ice water and then wit h methanol; and performing vacuum drying on the filter cake to obtain a faint yellow solid N-(3-chloro-4-(3-fluorophenylmethoxy)phenyl)-6-iodoquinazoline-4-amine. The route avoids the use of thionyl chloride or phosphorus oxychloride and reduces pollutions to the environment; besides, the process has high yield and simple operation and is suitable for industrial production.

Description

拉帕替尼合成中间体的制备工艺The preparation technology of synthetic intermediate of lapatinib

一、技术领域1. Technical field

本发明属于化工制药领域,尤其涉及一种拉帕替尼合成中间体的制备工艺。The invention belongs to the field of chemical industry and pharmacy, and in particular relates to a preparation process of a synthetic intermediate of lapatinib.

二、背景技术2. Background technology

拉帕替尼(Lapatinib)Lapatinib

化学名为N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-(5-((2-(甲砜基)乙基氨基)甲基)呋喃-2-基)喹唑啉-4-胺双(4-甲基苯磺酸盐)一水化合物,是由葛兰素史克公司研发的新型酪氨酸激酶抑制剂,用于治疗HER-2过度表达的晚期或转移性乳腺癌患者,2007年3月由美国FDA批准上市。N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺(1)是合成拉帕替尼的关键中间体,CAS登录号为231278-20-9。目前采用的制备工艺为:以5-碘-2-氨基苯甲酸为起始原料,经醋酸甲脒环合得到4-羟基-6-碘喹唑啉,经氯化亚砜或三氯氧磷氯化得到4-氯-6-碘喹唑啉,再与3-氯-4-(3-氟苯甲氧基)苯胺缩合得到1(附图1,路线1)。其中,4-氯-6-碘喹唑啉的合成采用4-羟基6-碘喹唑啉为原料,与过量氯化亚砜或三氯氧磷反应,后处理困难,环境污染大。The chemical name is N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2- Base) quinazolin-4-amine bis(4-methylbenzenesulfonate) monohydrate, a new type of tyrosine kinase inhibitor developed by GlaxoSmithKline, for the treatment of HER-2 overexpression For patients with advanced or metastatic breast cancer, it was approved for marketing by the US FDA in March 2007. N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine (1) is a key intermediate for the synthesis of lapatinib, and its CAS accession number is 231278-20-9. The preparation process currently used is: 5-iodo-2-aminobenzoic acid is used as the starting material, and 4-hydroxy-6-iodoquinazoline is obtained by cyclization of formamidine acetate, and thionyl chloride or phosphorus oxychloride Chlorination gives 4-chloro-6-iodoquinazoline, which is then condensed with 3-chloro-4-(3-fluorobenzyloxy)aniline to give 1 (accompanying drawing 1, route 1). Among them, the synthesis of 4-chloro-6-iodoquinazoline uses 4-hydroxyl 6-iodoquinazoline as a raw material, which reacts with excess thionyl chloride or phosphorus oxychloride, and the post-treatment is difficult and causes great environmental pollution.

三、发明内容3. Contents of the invention

技术问题:本专利提供一种拉帕替尼合成关键中间体N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺的新制备工艺。Technical problem: This patent provides a new method for the synthesis of key intermediate N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine from lapatinib Preparation Process.

技术方案:一种拉帕替尼合成中间体的制备工艺,工艺步骤为:将5-碘-2-氨基苯腈和DMF-DMA(N,N-二甲基甲酰胺二甲缩醛)混合,5-碘-2-氨基苯腈和DMF-DMA的投料比为1∶1-5,90-100℃加热回流1-2h,0.1MPa/70-80℃减压蒸馏10-30min除去过量的DMF-DMA,加入冰醋酸、3-氯-4-(3-氟苯甲氧基)苯胺,以5-碘-2-氨基苯腈质量计,所述冰醋酸的投料量为1-40ml/g,3-氯-4-(3-氟苯甲氧基)苯胺和5-碘-2-氨基苯腈投料摩尔比为1∶0.6-3,90-100℃加热回流1h,冷却至室温,倒入冰水中,抽滤,滤饼用冰水洗涤,再用甲醇洗涤,真空干燥,得到淡黄色固体N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺。Technical scheme: a preparation process for lapatinib synthetic intermediates, the process steps are: mixing 5-iodo-2-aminobenzonitrile and DMF-DMA (N,N-dimethylformamide dimethyl acetal) , the feeding ratio of 5-iodo-2-aminobenzonitrile and DMF-DMA is 1:1-5, reflux at 90-100°C for 1-2h, 0.1MPa/70-80°C for 10-30min under reduced pressure to remove excess DMF-DMA, add glacial acetic acid, 3-chloro-4-(3-fluorobenzyloxy)aniline, based on the mass of 5-iodo-2-aminobenzonitrile, the feeding amount of the glacial acetic acid is 1-40ml/ g, the molar ratio of 3-chloro-4-(3-fluorobenzyloxy)aniline and 5-iodo-2-aminobenzonitrile is 1:0.6-3, heated to reflux at 90-100°C for 1h, cooled to room temperature, Pour into ice water, filter with suction, wash the filter cake with ice water, then with methanol, and dry in vacuo to obtain light yellow solid N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6 - Iodoquinazolin-4-amine.

Figure G2009100333278D00021
Figure G2009100333278D00021

5-碘-2-氨基苯腈和DMF-DMA的投料摩尔比优选为1∶2-3。The molar ratio of 5-iodo-2-aminobenzonitrile and DMF-DMA is preferably 1:2-3.

以5-碘-2-氨基苯腈质量计,冰醋酸的投料量为5-20ml/g。Based on the mass of 5-iodo-2-aminobenzonitrile, the dosage of glacial acetic acid is 5-20ml/g.

3-氯-4-(3-氟苯甲氧基)苯胺和5-碘-2-氨基苯腈投料摩尔比为1∶1-1.5。The molar ratio of 3-chloro-4-(3-fluorobenzyloxy)aniline and 5-iodo-2-aminobenzonitrile is 1:1-1.5.

有益效果:该合成路线避免使用氯化亚砜或三氯氧磷,减少了对环境的污染;收率较高,操作简单,适合于工业化生产。Beneficial effects: the synthesis route avoids the use of thionyl chloride or phosphorus oxychloride, thereby reducing environmental pollution; the yield is high, the operation is simple, and it is suitable for industrial production.

四、附图说明4. Description of drawings

图1 N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺的制备工艺路线图。其中路线1为现有技术合成路线,路线2为本申请合成路线。Fig. 1 Process route diagram for the preparation of N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine. Wherein Route 1 is the prior art synthetic route, and Route 2 is the synthetic route of the present application.

五、具体实施方式5. Specific implementation

下面的实施例可使本专业技术人员全面的理解本发明,但不以任何方式限制本发明。The following examples can enable those skilled in the art to fully understand the present invention, but do not limit the present invention in any way.

实施例1  N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺(1)的制备Example 1 Preparation of N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine (1)

5-碘-2-氨基苯腈(18.4g,75mmol),DMF-DMA(N,N-二甲基甲酰胺二甲缩醛,40ml)加入到100ml茄形瓶中,90-100℃加热回流1h,减压蒸除过量的DMF-DMA,加入冰醋酸(100ml)、3-氯-4-(3-氟苯甲氧基)苯胺(15g,59.5mmol)加热回流1h,冷却至室温,倒入冰水(500ml)中,抽滤,滤饼用冰水(约500ml)洗涤,甲醇(1L)洗涤,真空干燥,得到淡黄色固体1 24.8g,收率82.4%。Add 5-iodo-2-aminobenzonitrile (18.4g, 75mmol), DMF-DMA (N,N-dimethylformamide dimethyl acetal, 40ml) into a 100ml eggplant-shaped bottle, heat to reflux at 90-100°C After 1h, excess DMF-DMA was distilled off under reduced pressure, glacial acetic acid (100ml), 3-chloro-4-(3-fluorobenzyloxy)aniline (15g, 59.5mmol) were added and heated to reflux for 1h, cooled to room temperature, poured Pour into ice water (500ml), filter with suction, wash the filter cake with ice water (about 500ml), wash with methanol (1L), and vacuum dry to obtain 124.8g of light yellow solid, yield 82.4%.

1H NMR(DMSO-d6,300Hz):5.26(s,2H);7.18(m,1H);7.34-7.26(m,3H);7.47(m,1H);7.56(d,J=8.7Hz,1H);7.75(d,J=8.8Hz,1H);8.03(s,1H);8.11(d,J=8.6Hz,1H);8.61(s,1H);8.95(s,1H);9.84(s,1H);13C NMR(DMSO-d6,300MHz):162.2(d,J=970Hz),156.3,154.7,149.7,148.7,141.2,139.6(d,J=30Hz),133.0,131.3,130.5(d,J=33Hz),129.7,123.9,123.2(d,J=10.8Hz),122.1,121.1,116.8,114.6(d,J=82.8Hz),114.3,114.0(d,J=87.3Hz),91.3,69.4;LC-MS:506[M+H]+ 1 H NMR (DMSO-d6, 300Hz): 5.26(s, 2H); 7.18(m, 1H); 7.34-7.26(m, 3H); 7.47(m, 1H); 7.56(d, J=8.7Hz, 1H); 7.75(d, J=8.8Hz, 1H); 8.03(s, 1H); 8.11(d, J=8.6Hz, 1H); 8.61(s, 1H); 8.95(s, 1H); 9.84( s, 1H); 13 C NMR (DMSO-d6, 300MHz): 162.2 (d, J=970Hz), 156.3, 154.7, 149.7, 148.7, 141.2, 139.6 (d, J=30Hz), 133.0, 131.3, 130.5 ( d, J=33Hz), 129.7, 123.9, 123.2(d, J=10.8Hz), 122.1, 121.1, 116.8, 114.6(d, J=82.8Hz), 114.3, 114.0(d, J=87.3Hz), 91.3 , 69.4; LC-MS: 506 [M+H] + .

实施例2 N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺(1)的制备Example 2 Preparation of N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine (1)

将5-碘-2-氨基苯腈和DMF-DMA混合,5-碘-2-氨基苯腈和DMF-DMA的投料摩尔比为1∶1-5,90-100℃加热回流1h,0.1MPa/70-80℃减压蒸馏30min除去过量的DMF-DMA,加入冰醋酸、3-氯-4-(3-氟苯甲氧基)苯胺,以5-碘-2-氨基苯腈质量计,所述冰醋酸的投料量为1-40ml/g,3-氯-4-(3-氟苯甲氧基)苯胺和5-碘-2-氨基苯腈投料摩尔比为1∶1-3,90-100℃加热回流1h,冷却至室温,倒入冰水中,抽滤,滤饼用冰水洗涤,再用甲醇洗涤,真空干燥,得到淡黄色固体N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺。Mix 5-iodo-2-aminobenzonitrile and DMF-DMA, the molar ratio of 5-iodo-2-aminobenzonitrile and DMF-DMA is 1:1-5, heat and reflux at 90-100°C for 1h, 0.1MPa /70-80°C under reduced pressure distillation for 30 minutes to remove excess DMF-DMA, add glacial acetic acid, 3-chloro-4-(3-fluorobenzyloxy)aniline, based on the mass of 5-iodo-2-aminobenzonitrile, The feeding amount of the glacial acetic acid is 1-40ml/g, and the molar ratio of 3-chloro-4-(3-fluorobenzyloxy)aniline and 5-iodo-2-aminobenzonitrile is 1: 1-3, Heat to reflux at 90-100°C for 1h, cool to room temperature, pour into ice water, filter with suction, wash the filter cake with ice water, then methanol, and dry in vacuo to obtain light yellow solid N-(3-chloro-4-(3 -fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine.

5-碘-2-氨基苯腈和DMF-DMA的投料摩尔比优选为1∶2-3。The molar ratio of 5-iodo-2-aminobenzonitrile and DMF-DMA is preferably 1:2-3.

以5-碘-2-氨基苯腈质量计,冰醋酸的投料量优选为5-20ml/g。Based on the mass of 5-iodo-2-aminobenzonitrile, the dosage of glacial acetic acid is preferably 5-20ml/g.

3-氯-4-(3-氟苯甲氧基)苯胺和5-碘-2-氨基苯腈投料摩尔比优选为1∶1-1.5。The molar ratio of 3-chloro-4-(3-fluorobenzyloxy)aniline to 5-iodo-2-aminobenzonitrile is preferably 1:1-1.5.

Claims (1)

1.一种拉帕替尼合成中间体的制备工艺,其特征在于工艺步骤为:将5-碘-2-氨基苯腈和DMF-DMA混合,5-碘-2-氨基苯腈和DMF-DMA的投料摩尔比为1∶2-3,90-100℃加热回流1-2h,0.1MPa/70-80℃减压蒸馏10-30min除去过量的DMF-DMA,加入冰醋酸、3-氯-4-(3-氟苯甲氧基)苯胺,以5-碘-2-氨基苯腈质量计,所述冰醋酸的投料量为5-20mL/g,3-氯-4-(3-氟苯甲氧基)苯胺和5-碘-2-氨基苯腈投料摩尔比为1∶1-1.5,90-100℃加热回流1h,冷却至室温,倒入冰水中,抽滤,滤饼用冰水洗涤,再用甲醇洗涤,真空干燥,得到淡黄色固体N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺。1. a preparation technique for lapatinib synthetic intermediate, is characterized in that processing step is: 5-iodo-2-aminobenzonitrile and DMF-DMA are mixed, 5-iodo-2-aminobenzonitrile and DMF- The feeding molar ratio of DMA is 1:2-3, heating and reflux at 90-100°C for 1-2h, 0.1MPa/70-80°C for 10-30min under reduced pressure distillation to remove excess DMF-DMA, add glacial acetic acid, 3-chloro- 4-(3-fluorobenzyloxy) aniline, in terms of 5-iodo-2-aminobenzonitrile mass, the charging capacity of the glacial acetic acid is 5-20mL/g, 3-chloro-4-(3-fluoro The molar ratio of benzyloxy)aniline and 5-iodo-2-aminobenzonitrile is 1:1-1.5, heated and refluxed at 90-100°C for 1h, cooled to room temperature, poured into ice water, filtered with suction, and the filter cake is washed with ice Washed with water, then with methanol, and dried in vacuo to give N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine as a pale yellow solid.
CN2009100333278A 2009-06-18 2009-06-18 Process for preparing lapatinib synthetic intermediate Expired - Fee Related CN101575319B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2009100333278A CN101575319B (en) 2009-06-18 2009-06-18 Process for preparing lapatinib synthetic intermediate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009100333278A CN101575319B (en) 2009-06-18 2009-06-18 Process for preparing lapatinib synthetic intermediate

Publications (2)

Publication Number Publication Date
CN101575319A CN101575319A (en) 2009-11-11
CN101575319B true CN101575319B (en) 2011-07-27

Family

ID=41270409

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009100333278A Expired - Fee Related CN101575319B (en) 2009-06-18 2009-06-18 Process for preparing lapatinib synthetic intermediate

Country Status (1)

Country Link
CN (1) CN101575319B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101792416B (en) * 2010-01-15 2011-10-05 南京医科大学 A kind of preparation technology of bosutinib
CN102532109B (en) * 2010-12-27 2015-05-13 浙江海正药业股份有限公司 Synthetic method of lapatinib and salt of lapatinib
CN102321076B (en) * 2011-07-07 2013-08-21 中国科学技术大学 Preparation method of lapatinib intermediate and analogues thereof
CN102675297B (en) * 2012-04-17 2014-10-15 人福医药集团股份公司 Preparation method of Lapatinib
CN103483324B (en) * 2012-06-12 2016-03-30 人福医药集团股份公司 The new preparation process of lapatinibditosylate
CN103539702B (en) * 2012-07-12 2016-03-30 陕西师范大学 The novel preparation method of N '-aryl-N, N-dimethyl carbonamidine
CN103159747A (en) * 2013-02-26 2013-06-19 常州鸿创高分子科技有限公司 Synthetic method of lapatinib
CN110698417B (en) * 2018-07-09 2020-11-20 新发药业有限公司 Preparation method of 6-substituent furyl-4-substituted amino quinazoline derivative and key intermediate thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006079833A1 (en) * 2005-01-31 2006-08-03 Arrow Therapeutics Limited Quinazoline derivatives as antiviral agents
WO2008056149A1 (en) * 2006-11-09 2008-05-15 Arrow Therapeutics Limited Quinazoline derivatives and pharmaceutical compositions containing them
CN101321740A (en) * 2005-10-07 2008-12-10 阿罗治疗有限公司 compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006079833A1 (en) * 2005-01-31 2006-08-03 Arrow Therapeutics Limited Quinazoline derivatives as antiviral agents
CN101321740A (en) * 2005-10-07 2008-12-10 阿罗治疗有限公司 compound
WO2008056149A1 (en) * 2006-11-09 2008-05-15 Arrow Therapeutics Limited Quinazoline derivatives and pharmaceutical compositions containing them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Tsou,HR.等.6-Substituted-4-(3-bromophenylamino) quinazolines as putative irreversible inhibitorsof epidermal growth factor receptor (EGFR) and humanepidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumour activity.《Journal of Medicinal Chemistry》.2001,第44卷(第17期),全文. *
王武伟等.N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺盐酸盐的合成.《化工中间体》.2008,(第11期),全文. *

Also Published As

Publication number Publication date
CN101575319A (en) 2009-11-11

Similar Documents

Publication Publication Date Title
CN101575319B (en) Process for preparing lapatinib synthetic intermediate
CN101402610A (en) Synthesis method of 4-(3-chlorine-4-fluorobenzene amino)-7-methoxy-6-[3-(4-morpholinyl)-propoxy] quinoline
JP2008546645A5 (en)
CN102558056B (en) Celecoxib and preparing method thereof
CN101701012A (en) Method for synthesizing triazine ring
CN106928184B (en) A kind of Ai Le replaces the preparation method of Buddhist nun
CN103626699A (en) Industrial preparation method of 4,7-dichloroquinoline
CN103304492B (en) The synthetic method of a kind of EGFR inhibitor Dacomitinib
CN101481350B (en) Synthetic process of norfloxacin
CN105037236B (en) Rui Boxini intermediates and preparation method thereof
CN101274914B (en) Asymmetric aromatic diamine containing xinhone-binaphthalene structure and its preparation method and application
CN104311485B (en) A kind of preparation method treating leukemic medicine bosutinib
CN101381303A (en) The preparation method of 3-fluorophthalic acid
CN103113309B (en) Bipyrimidyl dibenzene/diether/diamine and synthesis method thereof
CN103058936B (en) The preparation method of 4-[(the chloro-2-pyrimidyl of 4-) is amino] cyanophenyl
CN102786470A (en) Preparation method of indanylidene compound
CN102060717A (en) The synthetic method of 3-amino-4-bromophenol
CN102382100B (en) Preparation method of imatinib
CN101723901A (en) Method for preparing 2-propylbenzimidazole
CN105801495A (en) Synthesis and purification method of erlotinib hydrochloride
CN103319382B (en) The preparation method of 2-(amino) ethyl-methyl sulfone salt and intermediate thereof
CN102911125A (en) Method for preparing gefitinib intermediate
CN103539702B (en) The novel preparation method of N '-aryl-N, N-dimethyl carbonamidine
CN108947984B (en) Preparation method of pranlukast
CN104418845B (en) Prepare the method and intermediate of Lapatinib

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110727

Termination date: 20120618